Please assess the completion status of the following clinical trial:

Trial Title: Propanolol and Red Cell Adhesion Non-asthmatic Children Sickle Cell Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. diagnosis of HbSS or HbSBeta0Thal~2. age 10-17 years~3. Weight 30kg or greater~4. Hb 7mg/dL or greater~5. informed consent~Exclusion Criteria:~1. History of vaso-occlusive crisis during the past 6 weeks, or history of transfusion during the past 3 months.~2. pregnancy~3. history of heart failure, myocardial infarction, asthma, bradyarrythmias, hypotension, thyroid disease, diabetes, renal insufficiency~4. concurrent medications: any antihypertensive medication, diuretics, thyroid replacement medications, any arrythmia medication, insulin, hypoglycaemic medication~5. history of allergy to sulfonamides~6. elevated BUN or creatinine

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- cohort 1 10mg propranolol (Type: ACTIVE_COMPARATOR): first study arm will consist of 5 subjects who will be administered a dose of 10mg propanolol and followed 1-4 weeks.~Data safety and monitoring committee has reviewed the data for safety and instructed the study to continue based on the findings.
- cohort 2 20mg propranolol (Type: ACTIVE_COMPARATOR): This cohort will involve the administration of 5 subjects with 20mg propanolol. The data safety and monitoring committee will review the data for safety when the 5 subjects are recruited and instruct the study to continue depending on the findings.
- cohort 3 40mg propranolol (Type: ACTIVE_COMPARATOR): This cohort will involve the administration of 10 subjects with 40mg propanolol. The data safety and monitoring committee will review the data for safety when the 10 subjects are recruited and instruct the study to continue depending on the findings.

Based on this trial design, predict the completion outcome and termination type (if applicable).